Mutual of America Capital Management LLC Invests $2.34 Million in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Mutual of America Capital Management LLC purchased a new position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 64,214 shares of the company’s stock, valued at approximately $2,344,000. Mutual of America Capital Management LLC owned about 0.10% of SpringWorks Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Teacher Retirement System of Texas grew its holdings in shares of SpringWorks Therapeutics by 4.7% during the third quarter. Teacher Retirement System of Texas now owns 9,770 shares of the company’s stock worth $226,000 after purchasing an additional 441 shares during the last quarter. Royal Bank of Canada boosted its holdings in SpringWorks Therapeutics by 1.8% in the first quarter. Royal Bank of Canada now owns 26,465 shares of the company’s stock valued at $1,494,000 after acquiring an additional 479 shares during the last quarter. Sei Investments Co. boosted its holdings in SpringWorks Therapeutics by 4.0% in the second quarter. Sei Investments Co. now owns 14,198 shares of the company’s stock valued at $372,000 after acquiring an additional 549 shares during the last quarter. American International Group Inc. boosted its holdings in SpringWorks Therapeutics by 3.4% in the fourth quarter. American International Group Inc. now owns 17,036 shares of the company’s stock valued at $443,000 after acquiring an additional 553 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in SpringWorks Therapeutics by 4.0% in the third quarter. Envestnet Asset Management Inc. now owns 14,401 shares of the company’s stock valued at $411,000 after acquiring an additional 558 shares during the last quarter.

SpringWorks Therapeutics Price Performance

Shares of SWTX opened at $40.10 on Friday. SpringWorks Therapeutics, Inc. has a 52-week low of $18.00 and a 52-week high of $53.92. The business’s 50 day moving average price is $47.96 and its two-hundred day moving average price is $37.07.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.24) by ($0.20). The business had revenue of $5.45 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same quarter in the previous year, the business posted ($1.19) earnings per share. As a group, research analysts forecast that SpringWorks Therapeutics, Inc. will post -4.71 earnings per share for the current fiscal year.

Insider Transactions at SpringWorks Therapeutics

In other news, insider Daniel Pichl sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $50.10, for a total transaction of $751,500.00. Following the transaction, the insider now directly owns 45,212 shares of the company’s stock, valued at $2,265,121.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.61% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on SWTX shares. Wedbush upped their target price on SpringWorks Therapeutics from $60.00 to $70.00 and gave the company an “outperform” rating in a report on Monday, February 26th. HC Wainwright upped their target price on SpringWorks Therapeutics from $73.00 to $74.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. JPMorgan Chase & Co. upped their target price on SpringWorks Therapeutics from $73.00 to $74.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Barclays upped their target price on SpringWorks Therapeutics from $47.00 to $63.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Finally, Guggenheim started coverage on SpringWorks Therapeutics in a research note on Monday, February 5th. They issued a “buy” rating and a $75.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $68.00.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.